EVENTS

June 22-25, 2008
Dr. David Lester, Executive
VP, Corporate Development,
will be chairing and speaking
in a session at the Annual
DIA conference, Boston, MA.

 
June 10-11, 2008
Jonathan D. Rowe, PhD,
Sr. VP Strategy & Clinical
Innovation is an
invited
 panelist in an upcoming
 meeting of  the Linking
Strategy and Operations
Working Group sponsored
by the Palladium Group.


April 29, 2008
David S. Lester, PhD,
Senior VP of Strategy and
Corporate Development
speaks out on the future
of Pharma
.

April 12-16, 2008
Dr. James Willey, Founder
and Chief Science and
Medical Consultant, is
presenting at the American
Association for Cancer
 Research's Annual
Meeting in San Diego, CA.





Gene Express, Inc. integrates personalized medicine into clinical care by enabling the generation of standardized, comparable and quality controlled data for molecular diagnostic testing.  Our mission at Gene Express, Inc. is to accelerate the supply and delivery of quality, standardized molecular diagnostics in order to facilitate the implementation of personalized medicine as a standard of practice in healthcare.

Through research and strategic partnerships, Gene Express, Inc. plays an essential role in the discovery, validation, commercialization and delivery of gene expression-based molecular diagnostic tests. These tests aid physicians in the early diagnosis of disease, appropriate administration of medicines and monitoring of treatment response.  The research applications of our technology allow for selection of patient population for clinical trials, drug discovery and design, and accurate and repeatable basic research applications.

Gene Express, Inc.'s proprietary technology provides the link of data standardization and validation necessary to achieve the level of test quality assurance demanded by the industry.

Our late stage pipeline includes LungSentryDxTM. This prognostic test utilizes our standardized and multi-gene expression platform technology known as Standardized Reverse Transcription Polymerase Chain Reaction, (StaRT-PCRTM). The result is highly accurate, sensitive, specific, quality controlled data that can be directly compared between individuals, across testing sites, and over time. This analytical approach provides the necessary rigor to meet the FDA's criteria for In-Vitro Diagnostic Multivariate Index Assays (IVDMIAs) supporting the use of biomarkers for use in diagnostic, theranostic and prognostic tests.

Gene Express, Inc. fosters a proactive, productive, dynamic, and fluid relationship with clients, collaborators, and the healthcare community. We welcome strategic alliances and licensing opportunities that will bring innovative molecular diagnostics to market. As your partner of choice, our goal is to deliver all of your gene expression needs.













   

   
  Setting the Standard in Genomics.
    Discovery. 
Molecular Diagnostics.  Therapeutics.


 





















































PRESS RELEASE

April 21, 2008
Gene Express, Inc. today
announced that it has

signed an agreement
with the Division of
Patents & Licensing
Research Office.



March 17, 2008
Gene Express, Inc. today
announced that it has

appointed James L. Mulshine,
M.D. to its Scientific
Advisory Board.



January 7, 2008
Gene Express, Inc. today
announced the appoint of
Jonathan D. Rowe, Ph.D.
to Senior Vice President of
Strategy and Clinical
Innovation.




                                                                         Locations  |   Legal Notice  |  Privacy Policy  |  Contact Us